When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.

Ther Adv Neurol Disord · 2018 · PMC5791553 · PMID 29403543

Europe PMC DOI

hedged sentence

0.0577

closest p · 1.2× alpha

0.0577

boldest claim

The sentences

marginally significantp = 0.0577so close (0.05 < p ≤ 0.1)

Using results from both treatment periods, a marginally significant between-group difference favoring eculizumab was seen with respect to change in QMG score ( p = 0.0577).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.